A Comprehensive Review of Sarcoidosis Diagnosis and Monitoring for the Pulmonologist.
Biomarkers
Clinical evaluation
Diagnosis
Monitoring
Sarcoidosis
Journal
Pulmonary therapy
ISSN: 2364-1746
Titre abrégé: Pulm Ther
Pays: United States
ID NLM: 101687144
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
30
01
2021
accepted:
17
05
2021
pubmed:
7
6
2021
medline:
7
6
2021
entrez:
6
6
2021
Statut:
ppublish
Résumé
Sarcoidosis is a systemic granulomatous disease with heterogenous clinical manifestations. Here we review the diagnosis of sarcoidosis and propose a clinically feasible diagnostic work-up and monitoring protocol. As sarcoidosis is a systemic disease, a multidisciplinary approach is recommended for best outcomes. However, since the lungs are frequently involved, the pulmonologist is often the referral physician for diagnosis and management. When sarcoidosis is suspected, diagnosis needs to be confirmed and organ involvement/impairment assessed. This process is also required to establish whether the patient is likely to benefit from treatment, as many cases of sarcoidosis are self-limited and remit spontaneously. Whether or not treatment is started, effective regular follow-up is necessary to monitor changes in the disease, including extension, progression, remissions, flare-ups, and complications.
Identifiants
pubmed: 34091831
doi: 10.1007/s41030-021-00161-w
pii: 10.1007/s41030-021-00161-w
pmc: PMC8589876
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
309-324Informations de copyright
© 2021. The Author(s).
Références
Brito-Zerón P, Kostov B, Superville D, Baughman RP, Ramos-Casals M, Autoimmune Big Data Study Group. Geoepidemiological big data approach to sarcoidosis: geographical and ethnic determinants. Clin Exp Rheumatol. 2019;37(6):1052–64.
pubmed: 31498063
Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU. Pulmonary sarcoidosis. Lancet Respir Med. 2018;6(5):389–402.
pubmed: 29625772
Duchemann B, Annesi-Maesano I, Jacobe NC, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. Eur Respir J. 2017;50(2):1602419. https://doi.org/10.1183/13993003.02419-2016 .
doi: 10.1183/13993003.02419-2016
pubmed: 28775045
Prior C, Knight RA, Herold M. Pulmonary sarcoidosis: patterns of cytokine release in vitro. Eur Respir J. 1996;9:47–55.
pubmed: 8834333
Cinetto F, Agostini C. Advances in understanding the immunopathology of sarcoidosis and implications on therapy. Exp Rev Clin Immunol. 2016;12(9):973–88.
Miedema JR, Kaiser Y, Broos CE, Wijsenbeek MS, Grunewald J, Kool M. Th17-lineage cells in pulmonary sarcoidosis and Lofgren’s syndrome: Friend or foe? J Autoimmun. 2018;87:82–96. https://doi.org/10.1016/j.jaut.2017.12.012 ((Epub 2018 Jan 5.PMID: 29310925)).
doi: 10.1016/j.jaut.2017.12.012
pubmed: 29310925
Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170(12):1324–30.
pubmed: 15347561
Gupta D, Agarwal R, Aggarwal AN, et al. Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis. Eur Respir J. 2007;30(3):508–16.
pubmed: 17537780
Llanos O, Hamzeh N. Sarcoidosis. Med Clin North Am. 2019;103(3):527–34. https://doi.org/10.1016/j.mcna.2018.12.011 (Epub 2019 Feb 21 PMID: 30955519).
doi: 10.1016/j.mcna.2018.12.011
pubmed: 30955519
Baughman RP, Teirstein AS, Judson MA, et al. A Case Control Etiologic Study of Sarcoidosis (ACCESS) Research Group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1885–9.
pubmed: 11734441
Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis presentation, diagnosis and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):119–27.
pubmed: 23461074
Mañá J, Rubio-Rivas M, Villalba N, et al. Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: Cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain. Medicine (Baltimore). 2017;96(29):7595.
Schupp JC, Freitag-Wolf S, Bargagli E, et al. Phenotypes of organ involvement in sarcoidosis. Eur Respir J. 2019;69:77–85.
James WE, Koutroumpakis E, Saha B, Nathani A, Saavedra L, Yucel RM, Judson MA. Clinical features of extrapulmonary sarcoidosis without lung involvement. Chest. 2018;154(2):349–56.
pubmed: 29453944
Bahmer T, Watz H, Develaska M, et al. Physical activity and fatigue in patients with sarcoidosis. Respiration. 2018;95(1):18–26.
pubmed: 29131111
Cho PSP, Vasudevan S, Maddocks M, Spinou A, Chamberlain Mitchell S, Wood C, Jolley CJ, Birring SS. Physical inactivity in pulmonary sarcoidosis. Lung. 2019;197(3):285–93.
pubmed: 30888492
pmcid: 6520325
Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/world Association of Sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149–73.
pubmed: 10560120
Judson MA, Costabel U, Drent M, et al. Organ Assessment Instrument Investigators, The Wasog Sarcoidosis. The WASOG Sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):19–27.
pubmed: 24751450
Crouser ED, Maier LA, Wilson KC, et al. on behalf of the American Thoracic Society Assembly on Clinical Problems. Diagn Detect Sarcoidosis. 2020;201(8):e26–51. https://doi.org/10.1164/rccm.202002-0251ST (PMID: 32293205).
doi: 10.1164/rccm.202002-0251ST
Thillai M, Chang W, Chaudhuri N, et al. Sarcoidosis in the UK: insights from British Thoracic Society registry data. BMJ Open Respir Res. 2019;6(1):e000357. https://doi.org/10.1136/bmjresp-2018-000357 .
doi: 10.1136/bmjresp-2018-000357
pubmed: 30956798
pmcid: 6424275
Walsh SL, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med. 2014;2(2):123–30.
pubmed: 24503267
Judson MA. The three tiers of screening for sarcoidosis organ involvement. Respir Med. 2016;113:42–9.
pubmed: 27021579
Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. Br Med J. 1961;2(5261):1165–72.
pubmed: 14497750
pmcid: 1970202
Reddy GP, Ahuia J. Thoracic sarcoidosis: imaging patterns. Sem Roentgenol. 2019;54(1):59–65.
Slart RHJA, Glaudemans AWJM, Lancellotti P, et al. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. Eur Heart J Cardiovasc Imaging. 2017;18:1073–89.
Piekarski E, Benali K, Rouzet F. Nuclear imaging in sarcoidosis. Semin Nucl Med. 2018;48(3):246–60.
pubmed: 29626942
Keijsers RGM, Grutters JC. In Which Patients with Sarcoidosis Is FDG PET/CT Indicated? J Clin Med. 2020;9(3):890. https://doi.org/10.3390/jcm9030890 .
doi: 10.3390/jcm9030890
pmcid: 7141490
Vita T, Okada DR, Veillet-Chowdhury M, et al. Complementary value of cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the assessment of cardiac sarcoidosis. Circ Cardiovasc Imaging. 2018;11(1):e007030.
pubmed: 29335272
pmcid: 6381829
Miller EJ, Culver DA. Establishing an evidence-based method to diagnose cardiac sarcoidosis: the complementary use of cardiac Magnetic Resonance Imaging and FDG-PET. Circ Cardiovasc Imaging. 2018;11(1):e00740.
Trisolini R, Baughman RP, Spagnolo P, Culver DA. Endobronchial ultrasound-guided transbronchial needle aspiration in sarcoidosis: beyond the diagnostic yield. Respirology. 2019;24(6):531–42.
pubmed: 30912244
Meyer KC, Raghu G, Baughman RP, et al. An Official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185(12):1004–14.
pubmed: 22550210
d’Alessandro M, Carleo A, Cameli P, et al. BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases. Clin Exp Med. 2020. https://doi.org/10.1007/s10238-020-00608-5 .
doi: 10.1007/s10238-020-00608-5
pubmed: 32036463
Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest. 2007;132:207–13.
pubmed: 17625083
Chopra A, Kalkanis A, Judson MA. Biomarkers in sarcoidosis. Exp Rev Clin Immunol. 2016;12(11):1191–208.
Kampstra NA, van der Nat PB, Dijksman LM, et al. Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes. ERJ Open Res. 2019 Oct 30;5(4):00094–2019. https://doi.org/10.1183/23120541.00094-2019 .
doi: 10.1183/23120541.00094-2019
pubmed: 31687368
pmcid: 6819983
El Ameen AE, Herbort CP Jr. Comparison of retinal and choroidal involvement in sarcoidosis-related chorioretinitis using fluorescein and indocyanine green angiography. J Ophtalmic Vis Res. 2018;13:426–32.
Han YS, Rivera-Grana E, Salek S, Rosenbaum JT. Distinguishing uveitis secondary to sarcoidosis from idiopathic disease: cardiac implications. JAMA Ophthalmol. 2018;136(2):109–15.
pubmed: 29327057
pmcid: 5838604
Mochizuki M, Smith JR, Takase H, Kaburaki T, Acharaya NR, Rao NA, for the International Workshop on Ocular Sarcoidosis Study Group. Revised criteria International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis. Br J Ophthamol 2019; 103(10):1418–1422
Stern BJ, Royal W 3rd, Gelfand JM, et al. Definition and consensus diagnostic criteria for neurosarcoidosis: from the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018;75(12):1546–53.
pubmed: 30167654
Bathla G, Freeman CW, Moritani T, Song JW, Srivastava S, Soni N, Derdeyn C, Mohan S. Retrospective, dual-centre review of imaging findings in neurosarcoidosis at presentation: prevalence and imaging sub-types. Clin Radiol. 2020;75(10):796.e1-796.e9. https://doi.org/10.1016/j.crad.2020.05.008 .
doi: 10.1016/j.crad.2020.05.008
Saygin D, Jones S, Sundaram P, Calabrese LH, Messner W, Tavee JO, Hajj-Ali RA. Differentiation between neurosarcoidosis and primary central nervous system vasculitis based on demographic, cerebrospinal and imaging features. Clin Exp Rheumatol. 2020;124(2):135–8.
Tavee J, Culver D. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep. 2011;15(3):201–6.
pubmed: 21298560
Basantsova NY, Starshinova AA, Dori A, Zinchenko YS, Yablonskiy PK, Shoenfeld Y. Small-fiber neuropathy definition, diagnosis, and treatment. Neurol Sci. 2019;40(7):1343–2135.
pubmed: 30968230
Brines M, Culver DA, Ferdousi M, Tannemaat MR, van Velzen M, Dahan A, Malik RA. Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy. Sci Rep. 2018;8(1):4734.
pubmed: 29549285
pmcid: 5856845
Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis. J Am Coll Cardiol. 2016;68(4):411–21.
pubmed: 27443438
Juneau D, Nery P, Russo J, de Kemp RA, Leung E, Beanlands RSB, Birnie DH. How common is isolated cardiac sarcoidosis? Extra-cardiac and cardiac findings on clinical examination and whole-body
pubmed: 29306462
Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1305–12.
pubmed: 24819193
Terasaki F, Yoshinaga K. New guidelines for diagnosis of cardiac sarcoidosis in Japan. Ann Nucl Cardiol. 2017;3:42–5.
Chareonthaitawee P, Beanlands RS, Chen W, on behalf of the group, et al. Joint SNMMI-ASNC Expert Consensus Document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Med. 2017;58(8):1341–53.
pubmed: 28765228
pmcid: 6944184
Khan T, Selvakumar D, Trivedi S, Rao K, Harapoz M, Thiagalingam A, Denniss AR, Varikatt W. The value of endomyocardial biopsy in diagnosis and guiding therapy. Pathology. 2017;49(7):750–6.
pubmed: 29021100
Baughman RP, Lower EE. Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. Respir Med. 2013;107(12):2009–13.
pubmed: 24211131
Duréault A, Chapelon C, Biard L, et al. Severe infections in sarcoidosis: Incidence, predictors and long-term outcome in a cohort of 585 patients. Medicine (Baltimore). 2017;96(49):e8846.
Sweiss NJ, Salloum R, Gandhi S, et al. Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations. PLoS ONE. 2010;5(2):e9088.
pubmed: 20140091
pmcid: 2816716
Uzunhan Y, Nunes H, Jeny F, et al. Chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J. 2017;49(6):1602396. https://doi.org/10.1183/13993003.02396-201 .
doi: 10.1183/13993003.02396-201
pubmed: 28619957
Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J. 2017;50(4):1700465. https://doi.org/10.1183/13993003.00465-2017 .
doi: 10.1183/13993003.00465-2017
pubmed: 29051269
Brito-Zerón P, Acar-Denizli N, Sisó-Almirall A, et al. The burden of comorbidity and complexity in sarcoidosis: impact of associated chronic diseases. Lung. 2018;196(2):239–48.
pubmed: 29230534
Bours S, de Vries F, van der Bergh JPW, et al. Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort. Osteoporos Int. 2016;27:1603–10.
pubmed: 26630976
Ungprasert P, Crowson CS, Matteson EL. Association of sarcoidosis with increased risk of VTE: a population-based study. 1976 to 2013. Chest. 2017;151:425–30.
pubmed: 27687848
Ungprasert P, Crowson CS, Matteson EL. Risk of cardiovascular disease among patients with sarcoidosis: a population-based retrospective cohort study, 1976–2013. Eur Respir J. 2017;49(2):1601290. https://doi.org/10.1183/13993003.01290-2016 .
doi: 10.1183/13993003.01290-2016
pubmed: 28182567
pmcid: 5564441
Wu C-H, Chung PI, Wu CY, Chen YT, Chiu YW, Chang YT. Liu HN Comorbid autoimmune diseases in patients with sarcoidosis: a nationwide case-control study in Taiwan. J Dermatol. 2017;44(4):423–30.
pubmed: 27786368
Hendriks C, Drent M, De Kleijn W, Elfferich M, Wijnen P, De Vries J. Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: a prospective follow-up study. Respir Med. 2018;138S:S24–30.
pubmed: 29239767
Baughman RP, Nagai S, Balter M, et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:56–64.
pubmed: 21796892
Judson MA, Chaudhry H, Louis A, Lee K, Yucel R. The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respir Med. 2015;109(4):526–31.
pubmed: 25698652
pmcid: 4447298
Invernizzi A, Agarwal A, Mapelli C, Nguyen QD, Staurenghi G, Viola F. Longitudinal follow-up of choroidal granulomas using enhanced depth imaging optical coherence tomography. Retina. 2017;37(1):144–53.
pubmed: 27347644
Ning N, Guo HH, Iagaru A, Mittra E, Fowler M, Witteles R. Serial cardiac FDG-PET for the diagnosis and therapeutic guidance of patients with cardiac sarcoidosis. J Card Fail. 2019;25(4):307–11.
pubmed: 30825644
Oakada DR, Saad E, Wand AL, et al. Effect of corticosteroid dose and duration on 18-fluorodeoxyglucose positron Emission Tomography in cardiac sarcoidosis. JACC Cardiovasc Imaging. 2020. https://doi.org/10.1016/j.jcmg.2019.12.013 .
doi: 10.1016/j.jcmg.2019.12.013
Kiko T, Yoshihisa A, Kanno Y, et al. A multiple biomarker approach in patients with cardiac sarcoidosis. Int Heart J. 2018;59:996–100.
pubmed: 30101857
Panselinas E, Judson MA. Acute pulmonary exacerbations of sarcoidosis. Chest. 2012;142:827–36.
pubmed: 23032450
Rahaghi FF, Baughman RP, Saketkoo LA, et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev. 2020;29(155):190146. https://doi.org/10.1183/16000617.0146-2019 .
doi: 10.1183/16000617.0146-2019
pubmed: 32198218
Shlobin OA, Kouranos V, Barnett SD, et al. Physiological Predictors of Survival in Patients with Sarcoidosis Associated Pulmonary Hypertension: Results from an International Registry. Eur Respir J. 2020. https://doi.org/10.1183/13993003.01747-2019 .
doi: 10.1183/13993003.01747-2019
pubmed: 32139456
Duan J, Xu Y, Zhu H, et al. Relationship between CT activity score with lung function and the serum angiotensin converting enzyme in pulmonary sarcoidosis on chest HRCT. Medicine (Baltimore). 2018;97(36):e12205.
Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life. Am J Respir Crit Care Med. 2003;168(3):323–9. https://doi.org/10.1164/rccm.200211-1343OC (Epub 2003 May 8PMID: 12738606).
doi: 10.1164/rccm.200211-1343OC
pubmed: 12738606
Patel AS, Siegert RJ, Creamer D, et al. The development and validation of the King’s Sarcoidosis Questionnaire for the assessment of health status. Thorax. 2013 Jan;68(1):57–65. https://doi.org/10.1136/thoraxjnl-2012-201962 (Epub 2012 Oct 12PMID: 23065052).
doi: 10.1136/thoraxjnl-2012-201962
pubmed: 23065052
Judson MA, Mack M, Beaumont JL, Watt R, Barnathan ES, Victorson DE. Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure. Am J Respir Crit Care Med. 2015;191(7):786–95. https://doi.org/10.1164/rccm.201410-1785OC.PMID .
doi: 10.1164/rccm.201410-1785OC.PMID
pubmed: 25594886
de Vries J, Michielsen HJ, van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol. 2004;9:279–91.
pubmed: 15296678
Baughman RP, Sweiss N, Keijsers R, Birring SS, Shipley R, Saketkoo LA, Lower EE. Repository corticotropin for chronic pulmonary sarcoidosis. Lung. 2017;195(3):313–22.
pubmed: 28353116
pmcid: 5437201
Kampstra NA, Grutters JC, van Beek FT, et al. First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative. BMJ Open Respir Res. 2019;6(1):000394.
Bergantini L, d’Alessandro M, Vietri L, et al. Utility of serological biomarker’ panels for diagnostic accuracy of interstitial lung diseases. Immunol Res. 2020;68(6):414–21. https://doi.org/10.1007/s12026-020-09158-0 (Epub 2020 Oct 22. PMID: 33089426; PMCID: PMC7674352).
doi: 10.1007/s12026-020-09158-0
pubmed: 33089426
pmcid: 7674352